Westfield Capital Management acquired a new stake in Gilead Sciences shares, concurrent with an SEC filing on June 6, 2026.
1 report, 1 independent
Updated Jun 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Westfield Capital Management acquired a new stake in Gilead Sciences shares, concurrent with an SEC filing on June 6, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Gilead Sciences and Grifols traded on the NASDAQ stock exchange on September 8, 2026.
- Filings detail fund holdings for VGT with the Securities and Exchange Commission.
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- Gilead Sciences established a strategic alliance and contributed $5 billion, while Lakefront Biotherapeutics acquired assets from Ouro Medicines.
- JPMorgan Chase issues a new exchange-traded fund product, the Congress Large Cap Growth ETF, and discloses its holdings to the SEC.